Format

Send to

Choose Destination
Nat Rev Clin Oncol. 2019 Jun 12. doi: 10.1038/s41571-019-0227-z. [Epub ahead of print]

The changing therapeutic landscape of head and neck cancer.

Author information

1
Department of Otolaryngology, Wayne State University School of Medicine, Detroit, MI, USA.
2
Department of Medicine and Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
3
Department of Radiation Oncology, Stanford University, Palo Alto, CA, USA.
4
Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA. ferrisrl@upmc.edu.
5
Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA. ferrisrl@upmc.edu.
6
UPMC Hillman Cancer Center, Pittsburgh, PA, USA. ferrisrl@upmc.edu.

Abstract

Head and neck cancers are a heterogeneous collection of malignancies of the upper aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the changing therapeutic landscape of head and neck squamous cell carcinomas (HNSCCs) that can arise in the oral cavity, oropharynx, hypopharynx and larynx. We highlight developments in surgical and non-surgical therapies (mainly involving the combination of radiotherapy and chemotherapy), outlining how these treatments are being used in the current era of widespread testing for the presence of human papillomavirus infection in patients with HNSCC. Finally, we describe the clinical trials that led to the approval of the first immunotherapeutic agents for HNSCC, and discuss the development of strategies to decrease the toxicity of different treatment modalities.

PMID:
31189965
DOI:
10.1038/s41571-019-0227-z

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center